Research

Develop statistical and computational tools for personalized drug exposure prediction

• in-vitro model and data integration
• Animal model and data integration
• Physiological parameter integration
• PBPK model development

Literature mining and database construction

• PK data literature mining
• Drug interaction data literature mining
• PK ontology

Drug interaction discovery based on electronic medical records

• Drug interaction annotations
• Association between adverse events and drug interactions
• Experimental validation

Software and Databases
simCYP drug-drug interaction simulation
http://www.simcyp.com/
DiDB drug-drug interaction database
http://www.druginteractioninfo.org/
Drug Interactions drug interaction database
http://medicine.iupui.edu/flockhart/
NLME nonlinear mixed model regression
http://cran.r-project.org/src/contrib/Descriptions/nlme.html
NONMEM nonlinear mixed model regression
http://www.icondevsolutions.com/nonmem.htm
PROC NLMIXED nonlinear mixed model regression
http://www.sas.com/
Pharsight PK/PD model simulation and regression
http://www.pharsight.com/main.php
PBPKDDI physiological pharmacokinetic model based drug-drug interaction prediction
PKBUGS Bayes nonlinear regression
http://www.mrc-bsu.cam.ac.uk/bugs/winbugs/pkbugs.shtml
PK online resources
http://www.boomer.org/pkin/

Selected Publications

Quinney S.K., Zhang X., Lucksiri A.,  Gorski J.C., Li L., and Hall S.D. A Physiologically-Based Pharmacokinetic Model of Mechanism-Based Inhibition of CYP3A by Clarithromycin Drug Metab Dispos, 2010, 38, 241-8.

Wang Z.  Kim S., and Li L., Non-compartment model/compartment model transformation. BMC System Biology, 2010, 4, 1:S8. 

Borges S., Desta Z., Jin Y., Faouzi A., Robarge JD., Philip S., Nguyen A, Stearns V., Hayes D., Rae JM, Skaar TC, Flockhart DA, Li L. A Composite Functional Genetic and Co-Medication CYP2D6 Activity Score In Predicting Tamoxifen Drug Exposure Among Breast Cancer Patients. Journal of Clinical Pharmacology, 2010. 

Zhou J., Qin Z., Quinney S. K., Kim S., Wang Z., Hall D. S., and Li L. Equivalence Tests between Model based Drug-Drug Interaction Simulations and and Published Drug-Drug Interaction. Journal of Biopharmaceutical Statistics. 2009, 19, 641-657. 

Miao J., Jin Y., Marunde R.L., Kim S., Quinney S., Radovich M., Li L., and Hall S.D.  Association of Genotypes of the CYP3A Cluster with Midazolam Disposition In Vivo. Pharmacogenomics Journal, 2009, 9, 319-326. 

Wang Z, Kim S, Quinney SK, Guo Y, Hall SD, Rocha LM, Li L. Literature mining on pharmacokinetics numerical data: a feasibility study., J Biomed Inform. 2009, 42, 725-735. 

Zhou J., Qin Z., Quinney S. K., Kim S., Wang Z., Yu M., Chien J. Y., Lucksiri A., Hall D. S., and Li L. A new probabilistic rule for drug-drug interaction prediction. Journal of Pharmacokinetics and Pharmacodynamics. 2009, 36, 1-18.

Yu M., Kim S., Wang Z., Hall S, and Li L. Drug-drug interaction prediction: A Bayesian meta-analysis approach. Journal of Biopharmaceutical Statistics, 2008 18, 1063-1083.   

Li L. Discussion on parameter estimation for differential equations: a generalized smoothing approach. JRSS B. 2007, 69, 787-788.

Jones D. R., Ekins S., Li L.,  and Hall S. D. Computational approaches that predict metabolic intermediate complex formation with CYP3A4(+b 5). Drug Metab. and Dispos. 2007, 35(9):1466-75. 

Li L., Yu M., Chin R., Lucksiri A., Flockhart D., and Hall S. Drug-drug interaction prediction: A Bayesian meta-analysis approach. Statistics in Medicine, 2007, 26, 3700 – 3721.

Li L, Desai M., Desta Z., and Flockhart D. QT analysis: a complex answer to a ‘simple’ problem. Statistics in Medicine, 2004, 23, 2625-2643.

Li L,  Lin X, Brown M, Gupta S. and Lee K. A population pharmacokinetic model with time-dependent covariates measured with errors. Biometrics, 2004, 60, 451-460. 

Li L, Brown M, Lee K. and Gupta S. Estimation and inference for a spline-enhanced nonlinear population pharmacokinetic model. Biometrics, 2002; 58, 601-611.